FOR LIFE SCIENCES
Identify, educate and engage patients to complete recommended
immunizations and protect them from vaccine-preventable disease
Vaccine care gap opportunity
Vaccine-preventable diseases present a significant health risk to our communities. According to the CDC, over 50,000 adults die annually from vaccine-preventable diseases, and thousands suffer significant health issues that may lead to hospitalizations and other serious health concerns.1 The outbreak of COVID-19 has exacerbated the problem by significantly impacting vaccination rates across the US. Reductions in non-flu vaccinations have been seen across all age groups (11-65+yrs.), ranging from 46-60%.2 It is critical to reverse this trend in order to improve the overall public health of our communities. VAXENCETM is a solution designed to help.
What VAXENCE™ is, and how it works
VAXENCETM is a targeted immunization patient outreach and activation solution. Developed by Essence Patient Solutions and Inovalon†, leveraging the Inovalon ONE® Platform‡, VAXENCETM focuses on raising awareness of vaccine-preventable diseases, improving the initiation and completion of schedules for commercially available vaccines based on established guidelines, and supporting enhanced patient outcomes by identifying vaccine care gaps and educating patients on the benefits of closing those gaps.
The Inovalon ONE® Platform Accessible Network:
UNIQUE COVERED LIVES
UNIQUE COVERED LIVES
(Over 5 years period)
(providing medical, Rx claims, and lab results)
OF THE TOP 25 US HEALTH PLANS
VAXENCE™ provides targeted patient engagement to drive vaccinations
VAXENCETM allows life science companies to identify, address, close and capture vaccine treatment care gaps based on CDC guidelines across our extensive payer network. Vaccinations are driven through targeted patient and provider engagement and communications are received directly from the patients’ health plan, via preferred channel, in their primary language.
VAXENCE™ delivers timely setup and execution to get results
TO TARGET PATIENTS
WITHIN 90 DAYS OF
Currently supported VAXENCE™vaccines
Human Papillomavirus (HPV)
Measles, Mumps, Rubella and Varicella (MMRV)
Herpes Zoster (Shingles)
Meningococcal A / C / Y / W-135
Tetanus and Diphtheria (Td)
To get more information on how VAXENCE™ can help you achieve your business goals, or to speak to a member of our team, please
2 Filer W, Malone Y. 2019 to 2020 Decline in Administered Immunizations Across the Lifespan due to COVID ambulatory care and public health visit reductions. VaxCare. 2020.
†Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. Inovalon services over 100 of the leading health plans across the US, including 25 of the top 25.
‡The Inovalon ONE® Platform provides extensive industry connectivity, massive primary-source real-world datasets, sophisticated analytics, and powerful cloud-based technologies to improve the outcomes and economics of healthcare.
Disclaimer: all data on patients is de-identified and no patient specific information is shared with the vaccine manufacturer at any time.